{
    "id": "7823bcaf-46d8-4a8b-86ae-271fc60df433",
    "indications": "Posaconazole is an azole antifungal indicated as follows: • Posaconazole      is indicated for the prophylaxis of invasive Aspergillus and Candida infections in patients who are at high risk of developing these      infections due to being severely immunocompromised, such as hematopoietic      stem cell transplant (HSCT) recipients with graft-versus-host disease      (GVHD)or those with hematologic malignancies with prolonged neutropenia      from chemotherapy as follows: ( 1.2 ) o Posaconazole      delayed-release tablets: adults and pediatric patients 13 years of age      and older",
    "contraindications": "• Noxafil ® oral suspension is not substitutable with posaconazole delayed-release tablets or Noxafil ® powdermix for delayed-release oral suspension due to the differences in the dosing of each formulation. Therefore, follow the specific dosage recommendations for each of the formulations. (2.1, 2.2, 2.3, 2.8) • Administer Posaconazole delayed-release tablets with or without food. (2.1) Table 1. Recommended Dosage in Adult Patients and Pediatric Patients aged 13 years and older Indication Dose and Duration of Therapy Prophylaxis of invasive Aspergillus and Candida infections Delayed-Release Tablets † : Loading dose : 300 mg (three 100 mg delayed-release tablets) twice a day on the first day. Maintenance dose : 300 mg (three 100 mg delayed-release tablets) once a day, starting on the second day. Duration of therapy is based on recovery from neutropenia or immunosuppression. ( 2.2 , 2.3 )",
    "adverseReactions": "• Known hypersensitivity      to posaconazole or other azole antifungal agents. ( 4.1 ) • Coadministration of      posaconazole with the following drugs is contraindicated; posaconazole      increases concentrations and      toxicities of: o Sirolimus ( 4.2 , 5.1 , 7.1 ) o CYP3A4 substrates      (pimozide, quinidine): can result in QTc interval prolongation and cases      of torsades de pointes TdP ( 4.3 , 5.2 , 7.2 ) o HMG-CoA Reductase      Inhibitors Primarily Metabolized through CYP3A4 ( 4.4 , 7.3 ) o Ergot alkaloids ( 4.5 , 7.4 ) o Venetoclax: in      patients with chronic lymphocytic leukemia (CLL) or small lymphocytic      lymphoma (SLL) at initiation and during the ramp up phase (4.6, 5.10,      7.16)",
    "ingredients": [
        {
            "name": "POSACONAZOLE",
            "code": "6TK1G07BHZ"
        },
        {
            "name": "METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER",
            "code": "NX76LV5T8J"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM"
        },
        {
            "name": "XYLITOL",
            "code": "VCQ006KQ1E"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE, UNSPECIFIED",
            "code": "9XZ8H6N6OH"
        },
        {
            "name": "PROPYL GALLATE",
            "code": "8D4SNN7V92"
        },
        {
            "name": "POWDERED CELLULOSE",
            "code": "SMD1X3XO9M"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "SODIUM STEARYL FUMARATE",
            "code": "7CV7WJK4UI"
        },
        {
            "name": "POLYVINYL ALCOHOL, UNSPECIFIED",
            "code": "532B59J990"
        },
        {
            "name": "POLYETHYLENE GLYCOL 3350",
            "code": "G2M7P15E5P"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        }
    ],
    "organization": "Major Pharmaceuticals",
    "name": "POSACONAZOLE",
    "effectiveTime": "20250507"
}